Luminex Plc · CSELK:LUMX.N0000
Luminex — Investor Presentation (January 2021)
18 slides from Luminex's investor presentation, Jan 12, 2021
Slide 1: Investor Presentation January 2021
JANUARY 2021 Homi Shamir Chairman, President and CEO INVESTOR PRESENTATION
Slide 2: Safe Harbor Statement
complexity simplif ied. 2 SAFE HARBOR STATEMENT This presentation is being made exclusively to investors that are both institutional accredited investors (within the meaning of Rule 501 promulgated under the Securities Act of 1933, as amended (the “Securities Act”)) (“IAIs”) and qualified institutio
Slide 3: Luminex Corporation: Fully Embedded in Global Biomedical Science and Healthcare Enterprises
complexity simplif ied. 3 LUMINEX CORPORATION: FULLY EMBEDDED IN GLOBAL BIOMEDICAL SCIENCE AND HEALTHCARE ENTERPRISES Actionable solut ions across the biomedical spectrum Luminex is a biotech company providing molecular, proteomic, and cellular analysis tools and tests to life science and diagnostic
Slide 4: Luminex Corporation: Who We Are
complexity simplif ied. 4 LUMINEX CORPORATION: WHO WE ARE • Differentiated platforms and assays to address the needs of our clinical, biopharmaceutical, and research customers • Enabling molecular, proteomic, and cellular analysis DIVERSIFIED SOLUTIONS • Serving a growing $12B+ global life science m
Slide 5: Leading Customers & Partners
complexity simplif ied. 5 LEADING CUSTOMERS & PARTNERS
Slide 6: Luminex Addresses a $12B+ Global Market
complexity simplif ied. 6 LUMINEX ADDRESSES A $12B+ GLOBAL MARKET ACADEMIC GOVERNMENT BIOPHARMA / BIOTECH APPLIED TESTING HOSPITAL / REFERENCE LABS ARIES® VERIGENE® VERIGENE® II MAGPIX® LX200/ FM3D xMAP® INTELLIFLEX Guava® easyCyte™ ImageStream®
Slide 7: Company Is on Track to Nearly Triple Annual Revenue Since 2011
complexity simplif ied. 7 COMPANY IS ON TRACK TO NEARLY TRIPLE ANNUAL REVENUE SINCE 2011 $184M $203M $213M $227M $238M $270M $306M $315M $335M $417M 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021G $480M
Slide 8: Recurring Revenue Drives LMNX Growth
complexity simplif ied. 8 RECURRING REVENUE DRIVES LMNX GROWTH $0M $50M $100M $150M $200M $250M $300M $350M $400M $450M 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 of revenue is recurring 75% Assays Consumables Systems Other Royalties
Slide 9: Annual EBITDA Since 2011
complexity simplif ied. 9 ANNUAL EBITDA SINCE 2011 REVENUE GROWTH AND MARGIN FOCUS DRIVE EBITDA PROGRESSION $36M $37M $21M $42M $51M $41M $60M $52M $19M 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 LABCORP DEPARTURE RESTRUCTURING COSTS 2021 YTD thru Q3 $53.5M
Slide 10: Pandemic Solutions
PANDEMIC SOLUTIONS
Slide 11: Developing Solutions During the COVID-19 Pandemic
complexity simplif ied. 11 DEVELOPING SOLUTIONS DURING THE COVID-19 PANDEMIC PCR-BASED TESTS • Two Luminex PCR-based COVID-19 tests have already received EUA clearance • Run on ARIES® and NxTAG® Systems • Anticipate Q1 2021 EUA for a number of multiplex panels that have SARS-CoV-2 targets, including
Slide 12: Expanded Manufacturing to Meet Increased Demand
complexity simplif ied. 12 EXPANDED MANUFACTURING TO MEET INCREASED DEMAND Chicago/ VERIGENE® • ~25% increase in footprint ($8M facility purchase). Q1 2021 • 600K test capacity (VERIGENE II fully automated lines) • 1.2M test capacity (VERIGENE I) • $3.4M total investment (already paid) Madison/ Reag
Slide 13: Summary
Luminex. complexity simplified, SUVIVARY
Slide 14: Well-Positioned for Continued Growth
complexity simplif ied. 14 These efforts have allowed us to be well posit ioned for cont inued growth in profitability, while avoiding the “COVID-19 cliff” that many companies will be facing when the pandemic ult imately ends WELL-POSITIONED FOR CONTINUED GROWTH New growth opportunities from acquisi
Slide 15: 2021 Growth Drivers
2021 GROWTH DRIVERS VERIGENE® II LAUNCH Fully automated Random access Scalable Flexible pricing XMAP® INTELLIFLEX LAUNCH Increased sensitivity and dynamic range Customer convenience features Workflow automation enhancements Software UI improvements ADDITIONAL COVID-19 OFFERINGS NxTAG® RPP + SARS- Co
Slide 16: Beyond 2021 Growth Drivers
BEYOND 2021 GROWTH DRIVERS EFFECTIVE USE OF EXPANDING CASH POSITION M&A Increased dividend Share buyback Targeted R&D investment FURTHER MARKET PENETRATION ADDITIONAL ASSAY OFFERINGS All multiplex respiratory assays to include CoV-2 BSI: GP, GN & yeast CNS ARIES® menu expansion FURTHER INCREASE OF A
Slide 17: Luminex Is an Exciting Investment Opportunity
complexity simplif ied. 17 LUMINEX IS AN EXCITING INVESTMENT OPPORTUNITY: THE TIME IS NOW! SERVING MULTI-BILLION DOLLAR MARKETS ($12B+) RAZOR/ RAZORBLADE MODEL (75% ANNUITY) STRONG PROFITABILITY + CASH FLOW; CASH POSITION OF ~$310M; INCREASING DIVIDEND DIVERSIFIED PRODUCT OFFERINGS EXCITING NEW PROD
Slide 18: Thank You
Luminex. complexity simplified, THANK-YOU